158 related articles for article (PubMed ID: 36741698)
1. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
Hamada S; Kano S; Murai J; Suzuki T; Tsushima N; Mizumachi T; Suzuki M; Takashima T; Taniyama D; Sakamoto N; Fujioka Y; Ohba Y; Homma A
Front Oncol; 2022; 12():978875. PubMed ID: 36741698
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
3. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
[TBL] [Abstract][Full Text] [Related]
4. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
[TBL] [Abstract][Full Text] [Related]
5. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
[TBL] [Abstract][Full Text] [Related]
6. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
Takashima T; Taniyama D; Sakamoto N; Yasumoto M; Asai R; Hattori T; Honma R; Thang PQ; Ukai S; Maruyama R; Harada K; Kuraoka K; Tanabe K; Sasaki AT; Ohdan H; Morii E; Murai J; Yasui W
Br J Cancer; 2021 Jul; 125(1):65-77. PubMed ID: 33785877
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
[TBL] [Abstract][Full Text] [Related]
8. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Zhang B; Stewart CA; Wang Q; Cardnell RJ; Rocha P; Fujimoto J; Solis Soto LM; Wang R; Novegil V; Ansell P; He L; Fernandez L; Jendrisak A; Gilbertson C; Schonhoft JD; Byun J; Jones J; Anderson AKL; Aparicio A; Tran H; Negrao MV; Zhang J; Wang WL; Wistuba II; Wang J; Wenstrup R; Byers LA; Gay CM
Br J Cancer; 2022 Aug; 127(3):569-576. PubMed ID: 35440668
[TBL] [Abstract][Full Text] [Related]
9. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic upregulation of Schlafen11 renders
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
Nakata S; Murai J; Okada M; Takahashi H; Findlay TH; Malebranche K; Parthasarathy A; Miyashita S; Gabdulkhaev R; Benkimoun I; Druillennec S; Chabi S; Hawkins E; Miyahara H; Tateishi K; Yamashita S; Yamada S; Saito T; On J; Watanabe J; Tsukamoto Y; Yoshimura J; Oishi M; Nakano T; Imamura M; Imai C; Yamamoto T; Takeshima H; Sasaki AT; Rodriguez FJ; Nobusawa S; Varlet P; Pouponnot C; Osuka S; Pommier Y; Kakita A; Fujii Y; Raabe EH; Eberhart CG; Natsumeda M
Neuro Oncol; 2023 May; 25(5):899-912. PubMed ID: 36273330
[TBL] [Abstract][Full Text] [Related]
11. Modulation of SLFN11 induces changes in DNA Damage response in breast cancer.
Raynaud CM; Ahmed EI; Jabeen A; Sanchez A; Sherif S; Carneiro-Lobo TC; Awad A; Awartani D; Naik A; Thomas R; Decock J; Zoppoli G; Bedongnetti D; Hendrickx WRL
Cancer Cell Int; 2023 Nov; 23(1):291. PubMed ID: 38001424
[TBL] [Abstract][Full Text] [Related]
12. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13.
Fujiwara K; Maekawa M; Iimori Y; Ogawa A; Urano T; Kono N; Takeda H; Higashiyama S; Arita M; Murai J
iScience; 2023 Dec; 26(12):108529. PubMed ID: 38125019
[TBL] [Abstract][Full Text] [Related]
13. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Murai J; Thomas A; Miettinen M; Pommier Y
Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
[TBL] [Abstract][Full Text] [Related]
14. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
16. Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication.
Murai J; Ceribelli M; Fu H; Redon CE; Jo U; Murai Y; Aladjem MI; Thomas CJ; Pommier Y
Mol Cancer Ther; 2023 Aug; 22(8):985-995. PubMed ID: 37216280
[TBL] [Abstract][Full Text] [Related]
17. Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
Bednarikova M; Hausnerova J; Ehrlichova L; Matulova K; Gazarkova E; Minar L; Weinberger V
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625957
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
[No Abstract] [Full Text] [Related]
19. Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor.
Zhou J; Zhang MY; Gao AA; Zhu C; He T; Herman JG; Guo MZ
World J Gastrointest Oncol; 2024 May; 16(5):2060-2073. PubMed ID: 38764821
[TBL] [Abstract][Full Text] [Related]
20. SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents.
Gartrell J; Mellado-Largarde M; Clay MR; Bahrami A; Sahr NA; Sykes A; Blankenship K; Hoffmann L; Xie J; Cho HP; Twarog N; Connelly M; Yan KK; Yu J; Porter SN; Pruett-Miller SM; Neale G; Tinkle CL; Federico SM; Stewart EA; Shelat AA
Mol Cancer Ther; 2021 Nov; 20(11):2151-2165. PubMed ID: 34413129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
